Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 154Breast 146Genitourinary 117Gastrointestinal 61Head & Neck 47Gynecologic 21Sarcoma 14Tumor-Agnostic 13Other solid neoplasm 8Dermatologic 3Plasma cell 1Other 1Myeloid 1Lymphoid 1Endocrine 1

Conditions

Neoplasms 1Lymphoma 1

Interventions

Rituximab 530Cyclophosphamide 424Vincristine 219Doxorubicin 192fludarabine phosphate 176Etoposide 167Prednisone 166fludarabine 162Methotrexate 161Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 106Mycophenolic Acid 98ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 87Melphalan 85Calcium Dobesilate 82Bortezomib 80Peripheral Blood Stem Cell Transplantation 79Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Antilymphocyte Serum 55Brentuximab Vedotin 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Docetaxel × Lymphoid × Clear all
NCT00705874 2016-07-21

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Progen Pharmaceuticals

Phase 1 Completed
172 enrolled 13 charts
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡